BIOMEDICAL SOLUTIONS
Violatech operates in the field of large, highly specialized supplies of life-saving devices and equipment for public and private entities
H24 SUPPORT
Violatech can count on a group of dedicated people, with different professionalism and experience, able to assist Customers EVERY DAY, AT EVERY HOUR
BRAND NAMES
We work with the major international brands, quality distinguishes our company and the proof is being chosen by large medical facilities
Violatech
Biomedical solutions
Violatech, a young company by statute, but not by commitment, work and volume of business, was born in Rome in July 2008 from twenty years of experience of its director. Violatech operates in the field of highly specialized large-scale supplies of life-saving devices and devices, both to public and private entities, in most of the national territory.
Our news
Right heart remodeling after bicaval TricValve implantation in patients with severe tricuspid regurgitation.
From 16 to 19 May 2023, the specific program of P+F Products + Features GmbH in the forthcoming Euro PCR 2023 will be held at the Palais des Congrès in Paris.
Right heart remodeling after bicaval TricValve implantation in patients with severe tricuspid regurgitation.
From 16 to 19 May 2023, the specific program of P+F Products + Features GmbH in the forthcoming Euro PCR 2023 will be held at the Palais des Congrès in Paris.
Transcatheter heterotopic valve implantation with the TricValve system: focus on preoperative assessment and patient selection.
Nontreated severe symptomatic tricuspid valve regurgitation is associated with significant morbidity and mortality. When a surgical correction is not feasible due to high operative risk, transcatheter treatment of the tricuspid valve has been suggested as an interesting valuable option.
Transcatheter heterotopic valve implantation with the TricValve system: focus on preoperative evaluation and patient selection.
Untreated severe symptomatic tricuspid valve regurgitation is associated with significant morbidity and mortality. When surgical correction is not feasible due to high operative risk, transcatheter tricuspid valve treatment has been suggested as an attractive value option.